These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23415926)

  • 21. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
    Kantartzis K; Shepherd J
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary management of overactive bladder.
    Smith AL; Wein AJ
    Postgrad Med; 2012 Jan; 124(1):104-16. PubMed ID: 22314120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing urinary incontinence: what works?
    Giarenis I; Cardozo L
    Climacteric; 2014 Dec; 17 Suppl 2():26-33. PubMed ID: 25196507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in managing overactive bladder.
    Araklitis G; Baines G; da Silva AS; Robinson D; Cardozo L
    F1000Res; 2020; 9():. PubMed ID: 32968482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmentation enterocystoplasty in overactive bladder: is there still a role?
    Reyblat P; Ginsberg DA
    Curr Urol Rep; 2010 Nov; 11(6):432-9. PubMed ID: 20734172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intradetrusor injection of botulinum toxin for the management of refractory overactive bladder syndrome: an update.
    Al-Shaiji TF
    Surg Innov; 2013 Aug; 20(4):351-5. PubMed ID: 22964263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy-refractory overactive bladder: alternative treatment approaches].
    Knüpfer S; Hamann M; Naumann CM; Melchior D; Jünemann KP
    Urologe A; 2011 Jul; 50(7):806-9. PubMed ID: 21725649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posterior tibial nerve stimulation vs parasacral transcutaneous neuromodulation for overactive bladder in children.
    Barroso U; Viterbo W; Bittencourt J; Farias T; Lordêlo P
    J Urol; 2013 Aug; 190(2):673-7. PubMed ID: 23422257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
    Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
    Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
    Ellsworth P
    Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current management of overactive bladder.
    Cartwright R; Renganathan A; Cardozo L
    Curr Opin Obstet Gynecol; 2008 Oct; 20(5):489-95. PubMed ID: 18797274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding clinic options for overactive bladder.
    Bartley JM; Blum ES; Sirls LT; Peters KM
    Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
    Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
    Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 38. Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.
    Elser DM
    Postgrad Med; 2012 May; 124(3):42-9. PubMed ID: 22691898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
    Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
    Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.
    Arruda RM; Castro R; Sartori M; Girão MJ
    Curr Opin Obstet Gynecol; 2009 Oct; 21(5):412-4. PubMed ID: 19593131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.